
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc. demonstrated a positive trend in its financial performance for Q2 2025, with a net loss per share of $1.14, which is an improvement compared to the initial estimate of $1.22. The successful tolerance profile of OKI-219 across all dose levels, with no instances of hyperglycemia and only Grade 1 treatment-related adverse events, indicates the potential for favorable clinical outcomes. This combination of managing costs effectively while advancing a well-tolerated treatment position OnKure Therapeutics favorably within the clinical-stage biopharmaceutical industry.
Bears say
OnKure Therapeutics is projecting a full-year 2025 net loss of $4.56 per share, slightly improving from a previous estimate of $4.75 per share. The company faces significant risks, including potential negative clinical results for its lead asset, OKI-219, delays in advancing pipeline candidates, and challenges in obtaining timely regulatory approvals. Furthermore, competitive pressures from other mutant-selective PI3Kα inhibitors and long-term dilution concerns further contribute to a negative outlook for the company's financial health.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares